Formation of neutralizing antibodies during intranasal synthetic salmon calcitonin treatment of postmenopausal osteoporosis.
Nineteen patients with postmenopausal osteoporosis were treated with 200 u (15 nmol) synthetic salmon calcitonin (sCT) intranasally per day for 15 months. Six months after the start of the nasal administration of sCT, antibodies were recognized in 7, and after 15 months in 10 of the 19 patients studied. The half-maximal dilution of serum binding to 60 pmol/l [125I]sCT (dilution-50) ranged from 2 to 490, and half-maximal inhibition of [125I]sCT binding (60 pmol/l) from 91 to 221 pmol/l sCT. In a cultured breast cancer cell line (T47D) cAMP production was stimulated by sCT (EC50 70 pmol/l). Stimulated cAMP production by sCT (50 pmol/l) was reduced to between 4% and 23% in the presence of serum from patients with antibody dilution-50 of [125I]sCT binding exceeding 32. In patients with lower titer antibodies cAMP production was only marginally suppressed. The values of patients with postmenopausal osteoporosis were in the range of those of earlier studied patients with Paget's disease and clinical resistance to sCT. There was a linear relation between the antibody dilution-50 and the serum dilution required for half-maximal inhibition of cAMP production (P less than 0.01). In conclusion, neutralizing antibodies to sCT may contribute to the decreased responsiveness of bone mineral loss during prolonged treatment with sCT.
Muff
R
R
Department of Orthopedic Surgery, University of Zurich, Switzerland.
Dambacher
M A
MA
Fischer
J A
JA
D000281:Administration, Intranasal; D000368:Aged; D000917:Antibody Formation; D002116:Calcitonin / Q000008:administration & dosage / Q000276:immunology*; D005260:Female; D006801:Humans; D008875:Middle Aged; D009500:Neutralization Tests; D010001:Osteitis Deformans / Q000188:drug therapy / Q000276:immunology; D015663:Osteoporosis, Postmenopausal / Q000188:drug therapy* / Q000276:immunology*
C028815:salmon calcitonin; D002116:Calcitonin